This study wants to measure the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
Official registry: https://clinicaltrials.gov/study/NCT07712939 · Candid Therapeutics · enrollment listed as 105
Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are CND319. The registry lists allocation as na. This study wants to measure the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
They plan to enroll about 105 people at Melbourne. Taking part typically means an infusion or injection of a biologic plus check-ins.
A Phase 1, First-In-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CND319 in Healthy Participants and Patients With Rheumatic Diseases
Interventions: CND319
Primary outcome (registry wording): Incidence proportion and severity of treatment-emergent adverse events through end of study
Clinical Operations
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.
NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
NCT03414502 · Official ClinicalTrials.gov record · University of Nebraska
In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites.
NCT04748809 · Official ClinicalTrials.gov record · University of California, San Diego
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary